Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Emily Holthuis"'
Autor:
Carlos E. Durán, Judit Riera-Arnau, Shahab Abtahi, Romin Pajouheshnia, Vjola Hoxhaj, Magdalena Gamba, Ema Alsina, Mar Martin-Perez, Patricia Garcia-Poza, Ana Llorente-Garcia, Diana Gonzalez-Bermejo, Luisa Ibánez, Mònica Sabaté, Xavier Vidal, Elena Ballarín, Gabriel Sanfélix-Gimeno, Clara Rodríguez-Bernal, Salvador Peiró, Aníbal García-Sempere, Francisco Sanchez-Saez, Valentina Ientile, Ylenia Ingrasciotta, Claudio Guarneri, Matilde Tanaglia, Michele Tari, Ron Herings, Eline Houben, Karin Swart-Polinder, Emily Holthuis, Consuelo Huerta, Rosa Gini, Giuseppe Roberto, Claudia Bartolini, Olga Paoletti, Giorgio Limoncella, Anna Girardi, Giulia Hyeraci, Morten Andersen, Sarah Brøgger Kristiansen, Christine Erikstrup Hallgreen, Olaf Klungel, Miriam Sturkenboom
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women.Objective: To measure the impact of the 2018 revis
Externí odkaz:
https://doaj.org/article/97c75f28f2b14a79838ac1ce448b894e
Autor:
Emily Holthuis, Elisabeth Smits, George Spentzouris, Dominik Beier, Dirk Enders, Rosa Gini, Claudia Bartolini, Giampiero Mazzaglia, Fernie Penning-van Beest, Ron Herings
Publikováno v:
Holthuis, E, Smits, E, Spentzouris, G, Beier, D, Enders, D, Gini, R, Bartolini, C, Mazzaglia, G, Penning-van Beest, F & Herings, R 2022, ' Increased Risk of Stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs) : Real-World Analyses Using a Nested Case–Control Study from The Netherlands, Italy and Germany ', Drugs-Real World Outcomes, vol. 9, no. 4, pp. 597-607 . https://doi.org/10.1007/s40801-022-00317-3
Drugs-Real World Outcomes, 9(4), 597-607. Springer International Publishing AG
Drugs-Real World Outcomes, 9(4), 597-607. Springer International Publishing AG
Background: A high degree of adherence to direct oral anticoagulants is essential for reducing the risk of ischaemic stroke and systemic embolism in patients with atrial fibrillation, owing to the rapid decline in anticoagulation activity when doses